Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. (not Lifemd, Inc.) on April 7, 2016, reporting events occurring on April 1, 2016. The filing details the entry into a Material Definitive Agreement regarding the Company's joint venture, Innate Scientific, LLC (legally ImmuDyne PR LLC), which focuses on a skin care regime using the Company's proprietary ingredients.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It notes that the joint venture was a contributor to revenues in the fourth quarter of 2015 but does not quantify that contribution.
Material Changes
- Ownership Increase: Immudyne, Inc. increased its ownership and voting interest in the joint venture to 78.16667%.
- Stock Issuance: The Company issued 1,000,000 restricted shares of common stock to JLS Ventures, LLC and 1,000,000 restricted shares to American Nutra Tech LLC as consideration for operational management services.
- Agreement Amendments: Existing agreements with Taggart International Trust and American Nutra Tech were amended and restated.
Guidance, Outlook, and Contingencies
Contingent Share Rescission: The issuance of the 2,000,000 restricted shares may be rescinded if the joint venture (Innate) does not distribute at least $500,000 to the Company by December 31, 2016.
Future Issuances: Additional shares and/or options may be issued to service providers upon the achievement of certain financial milestones by Immudyne PR, as specified in the Service Agreements.
Management Commentary: The filing states that Innate Scientific was established to launch a complete skin care regime and contributed to revenues in Q4 2015.
Investor Verification Checklist
- Verify the exact terms of the Operating Agreement (Exhibit 10.9) regarding the 78.16667% ownership stake.
- Confirm the specific financial milestones required for the issuance of additional shares or options under the Service Agreements (Exhibits 10.10 and 10.11).
- Monitor the joint venture's performance to determine if the $500,000 distribution threshold is met by December 31, 2016, which dictates whether the 2,000,000 issued shares remain outstanding.
- Review the full text of the agreements to understand the scope of operational management services provided by JLS and American Nutra Tech.